Trial Information

Official Title: Efficacy, Safety and Pharmacokinetics of SPK-843 in the Treatment of Pulmonary Mycosis. Open Label Phase III Clinical Study

Summary

Recruitment of at least 10 adult patients (men and women) among individuals affected and admitted to the hospitals identified for the clinical study. All patients shall be between 18 and 75 years of age, with confirmed diagnosis of cryptococcosis or aspergillosis . During therapy (14 days) and examination (28 days), the patients will be subject to 7 doctor's visits (day 1,3,7,10,14,21, and 28).

Phase: Phase 3

Sponsor: Proaparts srl

Overall Contacts:

Luigi Allegra, Ph.D
39 02 55033781
luigi.allegra@unimi.it

Adolfo Gasparetto, Dr.
Phone: 39 0429 652545
adolfogasparetto@nextrasearch.it